Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paroxetine - Novo Nordisk

Next Previous
Drug Profile

Paroxetine - Novo Nordisk

Alternative Names: Aropax; BRL 29060; BRL 29060A; Deroxat; Divarius; FG 7051; Frosinor; Motivan; NNC 207051; Paxil; Paxil CR; Seroxat; SI 211103; Tagonis

Latest Information Update: 28 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer GlaxoSmithKline KK; GSK; Novo Nordisk; Scios; Vectura
  • Class Antidepressants; Anxiolytics; Benzodioxoles; Fluorobenzenes; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Depressive disorders; Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
  • No development reported Anxiety disorders

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Anxiety-disorders(In volunteers) in Mexico (PO, Tablet)
  • 29 Sep 2023 GlaxoSmithKline plans a phase I trial for Anxiety disorders (In volunteers) in September 2023 (PO) (NCT06065735)
  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top